Bill > HB2060

This bill introduces pain parity requirements for both Medicaid and commercial insurance in Pennsylvania, ensuring that non-opioid pain medications receive equal treatment compared to opioid medications. For Medicaid, the bill requires that non-opioid drugs approved by the FDA for pain treatment cannot be disadvantaged on the statewide preferred drug list, meaning they cannot face more restrictive coverage, prior authorization, or step therapy requirements than opioid drugs. Similarly, for commercial insurance, the bill mandates that insurers cannot impose more restrictive coverage criteria, utilization controls, or cost-sharing requirements on non-opioid pain medications compared to opioid pain medications. The provisions apply immediately upon a non-opioid drug's FDA approval for pain treatment and cover both Medicaid programs and contracts with managed care organizations, as well as commercial insurance formularies. By implementing these requirements, the bill aims to provide patients with more equitable access to pain management treatments and prevent potential bias against non-opioid pain medications. The bill will take effect 60 days after its passage.

Health and Social Services

https://www.palegis.us/legislation/bills/2025/hb2060